CA2137832C - Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain - Google Patents

Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain Download PDF

Info

Publication number
CA2137832C
CA2137832C CA002137832A CA2137832A CA2137832C CA 2137832 C CA2137832 C CA 2137832C CA 002137832 A CA002137832 A CA 002137832A CA 2137832 A CA2137832 A CA 2137832A CA 2137832 C CA2137832 C CA 2137832C
Authority
CA
Canada
Prior art keywords
formula
alkyl
product
ethyl acetate
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002137832A
Other languages
English (en)
Other versions
CA2137832A1 (fr
Inventor
Dennis J. Hoover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CA2137832A1 publication Critical patent/CA2137832A1/fr
Application granted granted Critical
Publication of CA2137832C publication Critical patent/CA2137832C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composé de la formule (I) permettant de prévenir ou de traiter efficacement l'hypertension, l'insuffisance cardiaque, l'infarctus du myocarde, l'hypertrophie cardiaque et du ventricule gauche, les affections des artères coronaires comprenant l'infarctus du myocarde, l'hypertrophie vasculaire, ainsi que des lésions vasculaires résultant d'affections rénales diabétiques et non diabétiques, ainsi que des lésions vasculaires associées à l'angioplastie et l'aethéroma.
CA002137832A 1992-06-12 1993-04-23 Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain Expired - Fee Related CA2137832C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12
US897,723 1992-06-12
PCT/US1993/003625 WO1993025574A1 (fr) 1992-06-12 1993-04-23 Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine

Publications (2)

Publication Number Publication Date
CA2137832A1 CA2137832A1 (fr) 1993-12-23
CA2137832C true CA2137832C (fr) 2000-09-26

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137832A Expired - Fee Related CA2137832C (fr) 1992-06-12 1993-04-23 Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain

Country Status (5)

Country Link
EP (1) EP0644892A1 (fr)
JP (1) JP2668003B2 (fr)
CA (1) CA2137832C (fr)
FI (1) FI932695A (fr)
WO (1) WO1993025574A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
NZ334543A (en) * 1996-09-10 2000-06-23 Thomae Gmbh Dr K Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
IL129407A0 (en) * 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
KR20000052775A (ko) * 1996-10-25 2000-08-25 가마쿠라 아키오 신규한 헤테로사이클릭 아미드 화합물 및 의약으로서의 그의 용도
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6300337B1 (en) 1998-02-17 2001-10-09 Nippon Kayaku Kabushiki Kaisha Acetamide derivative and use thereof
KR20010074838A (ko) * 1998-08-20 2001-08-09 요시다 쇼지 안 순환 장해의 예방 또는 치료제
US6432978B1 (en) * 1998-12-01 2002-08-13 Meiji Seika Kaisha, Ltd. SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities
WO2001032214A1 (fr) 1999-11-01 2001-05-10 Suntory Limited Inhibiteurs diriges contre le depot de lipides dans les vaisseaux, contenant des substances inhibant la chymase
US6500835B2 (en) 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
HUP0201287A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for various eosinphilia-related diseases containing quinazoline derivative chymase inhibitors as the active ingredient
HUP0201282A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient
CA2411165A1 (fr) * 2000-05-02 2002-12-11 Meiji Seika Kaisha, Ltd. Nouveaux derives indoliques presentant des activites inhibitrices de chymase et leur procede de preparation
AU2002222933A1 (en) * 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
WO2002059077A1 (fr) 2001-01-26 2002-08-01 Takeda Chemical Industries, Ltd. Derivés aminoéthanol
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
KR101187693B1 (ko) 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2010068760A2 (fr) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. Nouveaux peptides 4-amino-4-oxobutanoyl utiles en tant qu'inhibiteurs de la réplication virale
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
DK3472149T3 (da) 2016-06-21 2023-11-27 Orion Ophthalmology LLC Heterocykliske prolinamidderivater
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ZA905737B (en) * 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
ATE181925T1 (de) * 1991-05-23 1999-07-15 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau

Also Published As

Publication number Publication date
WO1993025574A1 (fr) 1993-12-23
FI932695A0 (fi) 1993-06-11
FI932695A (fi) 1993-12-13
EP0644892A1 (fr) 1995-03-29
JP2668003B2 (ja) 1997-10-27
JPH07507069A (ja) 1995-08-03
CA2137832A1 (fr) 1993-12-23

Similar Documents

Publication Publication Date Title
CA2137832C (fr) Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain
RU2142469C1 (ru) Пептидные производные, их стереоизомеры или физиологически приемлемые соли, обладающие противотромбозной, противосвертывающей или противовоспалительной активностью, способ их получения, фармацевтическая композиция, способ подавления тромбина, способ подавления кининогеназ, применение соединений в качестве исходных в синтезе ингибитора тромбина
KR900008004B1 (ko) 펩티다제 억제물의 제조방법
US6992105B2 (en) Dipeptide derivatives
US5430023A (en) Tripeptide antithrombotic agents
US6432921B2 (en) Thrombin inhibitors
US20060194742A1 (en) Pyrane derivatives as both ACE- and NEP-inhibitors
AU2002314067A1 (en) Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
US6218365B1 (en) Serine protease inhibitors
PL188411B1 (pl) Nowe inhibitory trombiny i ich zastosowanie
HUT61744A (en) Process for producing renin inhibiting alkylaminocarbonyl group-substituted heterocyclic compounds
CA2006839A1 (fr) Inhibiteurs de la renine contenant des amides a groupement dihydroxy en position c-terminale
CA2013475A1 (fr) Derives d'acides amines
JPH0688979B2 (ja) 化合物
RU2172321C2 (ru) Ингибиторы сериновых протеаз
KR880001007B1 (ko) 비사이클릭 화합물의 제조 방법
JPH01110695A (ja) アミノ酸誘導体その製造方法及び血圧降下剤
INAGAKI et al. P1—P1’Cleavage Site “
MXPA98007090A (en) Inhibitors of serine prote

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed